Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has earned an average recommendation of “Buy” from the twelve brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $50.33.
A number of equities research analysts have issued reports on SUPN shares. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 10th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price for the company. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, November 7th. Finally, Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd.
In other news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total transaction of $2,178,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 145,750 shares of company stock valued at $6,173,173. Insiders own 6.70% of the company’s stock.
Supernus Pharmaceuticals (NASDAQ SUPN) traded down $2.95 on Friday, reaching $43.55. 904,600 shares of the company traded hands, compared to its average volume of 706,475. The firm has a market capitalization of $2,390.00, a price-to-earnings ratio of 39.59 and a beta of 1.17. Supernus Pharmaceuticals has a 52-week low of $23.10 and a 52-week high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts anticipate that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.